Piramal Pharma Limited (PPL) announced that Yapan Bio has expanded its capabilities with a new process development facility at Genome Valley, Hyderabad, India.

PPL holds a strategic minority stake in Yapan and markets its services through Piramal Pharma Solutions (PPS), an industry-leading, patient-centric Contract Development and Manufacturing Organization (CDMO) serving the global pharmaceutical and biotech market.

With this expansion, Yapan has enhanced its ability to support end-to-end development and manufacturing of RNA, DNA and gene therapy products starting from plasmids. The expansion includes three upstream suites (including Bio-Safety Level-2 containment), a downstream process development lab, an analytical development lab, and supporting infrastructure. The new labs will allow Yapan to optimize the utilization of the GMP facility to support the manufacturing of clinical trial material for the clients.

The new facility was inaugurated by KT Rama Rao, Minister for Municipal Administration & Urban Development, Industries & Commerce, and Information Technology of Telangana; Nandini Piramal, Chairperson, Piramal Pharma; Harinder S. Sikka, Group Director, Strategic Business, Piramal Enterprises; and Atin Tomar & Nirav Desai, Founders of Yapan Bio. Jayesh Ranjan, IAS, Principal Secretary (IT, E&C), Government of Telangana, Shakthi Nagappan, Director (LS), Government of Telangana, and Pachipala Dora Swamy, Touchstone Property Developers, were also present during the event.